A Randomised, Double-Blind, Parallel-Group, Fixed Dose Study Exploring the Efficacy and Safety of Lu AE58054 as Augmentation Therapy to Risperidone in Patients With Schizophrenia.
Phase of Trial: Phase II
Latest Information Update: 05 Jan 2013
At a glance
- Drugs Idalopirdine (Primary) ; Risperidone
- Indications Schizophrenia
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 03 Jul 2012 Company added in the association field as reported by EudraCT.
- 01 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.